Clinical trials: Respiratory Allergy
Airway Inflammation, Asthma
An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients
This is a randomised, active-comparator, open-label, parallel-group, multicentre phase IV exploratory study to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using SABA…
- Trial name
- NCT03924635
- Testing
- SYMBICORT and salbutamol
- Where
- 6 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus…
- Trial name
- ORCHID (NCT04157335)
- Testing
- Benralizumab 30 mg
- Where
- 116 sites in United States, Argentina and 15 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Seasonal Allergic Rhinitis
Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult
Allergic rhinitis (AR) affects large population worldwide, the most commonly used medication include anti-histamine, nasal spray and anti-LTRAs inhibitors (leukotriene receptor antagonists), Even after those first-line treatment…
- Trial name
- NCT06046391
- Testing
- LP-003 dose 1, LP-003 dose 2
- Where
- 17 sites in China
- Volunteers
- 180 people
- Sponsor
- Longbio Pharma
Allergic Rhinitis
A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of…
- Trial name
- NCT02557633
- Testing
- Grass MATA MPL 10200, Grass MATA MPL 18200
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Allergy Therapeutics
Asthma
The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics
This study will be the First Time in Human Study (FTIH) aiming to assess the safety and tolerability of GW805858 for both single and repeat dose.
- Trial name
- NCT00453791
- Testing
- GW805858
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E-RS) in Subjects With Asthma
Asthma and chronic obstructive pulmonary disease (COPD) are chronic inflammatory conditions involving the small airways with airflow limitations resulting from genetic and environmental interactions.
- Trial name
- NCT03344406
- Testing
- Telephonic interviews, E-RS: COPD, Supplemental asthma items
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Asthma
Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus
The purpose of this study is to compare the test product Salmeterol/fluticasone Easyhaler with the reference product Seretide Diskus in terms of drug absorbed in the bloodstream.
- Trial name
- NCT01766843
- Testing
- Seretide Diskus and charcoal, Seretide Diskus, SF Easyhaler and charcoal
- Where
- Finland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Asthma
A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma
The primary objective will be to compare the Eurofarma and Alenia formulations regarding their impact on the pulmonary function of mild to moderate persistent asthma patients and the secondary objective will be to compare the…
- Trial name
- UNIK (NCT01167010)
- Testing
- Formoterol/Budesonide, Foraseq, Alenia
- Where
- 5 sites in Brazil
- Volunteers
- 552 people
- Sponsor
- Eurofarma Laboratorios S.A.
Asthma, Allergy
ATEM (Alvesco Non-interventional Study)
The aim of the study is to evaluate the efficacy of Alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season.
- Trial name
- ATEM (NCT01147224)
- Testing
- Alvesco
- Where
- 79 sites in Austria
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Asthma
A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects
The study is designed in two phases: single-dose administration and multiple-dose administration. A randomized, double-blind, placebo-controlled trial design was used to evaluate the safety, tolerability, pharmacokinetic…
- Trial name
- NCT06449859
- Testing
- TQC2938 Injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Asthma
Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
GSK3772847, an anti-interleukin (IL)33 receptor monoclonal antibody, is a novel treatment for asthma. This is a phase 2a study which aims to evaluate efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD)…
- Trial name
- NCT03207243
- Testing
- GSK3772847, Fluticasone propionate/salmeterol, Fluticasone propionate
- Where
- 64 sites in United States, Australia and 4 more
- Volunteers
- 165 people
- Sponsor
- GlaxoSmithKline
Asthma
Study in Patients With Asthma
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective in the treatment of asthma compared to the control drug.
- Trial name
- NCT00215397
- Testing
- Formoterol Fumarate
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dey
Asthma
Measuring Exhaled Nitric Oxide (eNO) Using the Apieron INSIGHT System and the Aerocrine NIOX System
Collection of quantitative data to demonstrate the accuracy (bias) and precision (repeatability) of the Apieron INSIGHT(tm) eNO Breath System as compared to the FDA cleared NIOX eNO Breath System when testing is performed by…
- Trial name
- NCT00739531
- Testing
- Exhaled nitric oxide (eNO)
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Apieron
Asthma
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years with Asthma during 12…
- Trial name
- CHASE 3 (NCT02091986)
- Testing
- Symbicort pMDI, Budesonide pMDI
- Where
- 70 sites in United States, Mexico and 2 more
- Volunteers
- 882 people
- Sponsor
- AstraZeneca
Bronchial Asthma
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with bronchial asthma
- Trial name
- NCT06637254
- Testing
- HSK31858
- Where
- China
- Volunteers
- 219 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Allergy, Respiratory Disease
Impact of AIT on Allergic Rhinitis and Asthma
The study will assess the effectiveness of AIT treatment in real clinical practice in Germany.
- Trial name
- NCT04125888
- Testing
- Allergy immunotherapy (AIT)
- Where
- Denmark
- Volunteers
- 92,048 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis
ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
A multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT, a Combination of Contiguous Overlapping Peptides Derived from Bet v 1, in Adults with…
- Trial name
- ATIBAR (NCT02943720)
- Testing
- AllerT
- Where
- 36 sites in Denmark, Finland and 6 more
- Volunteers
- 421 people
- Sponsor
- Anergis
Asthma
Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.
Primary objective: To demonstrate the efficacy of ciclesonide, compared to placebo, at 80 μg twice daily (BID) or 40 μg BID for 12 weeks in patients with persistent asthma.
- Trial name
- NCT00392288
- Testing
- Ciclesonide
- Where
- 6 sites in United States, Hungary and 4 more
- Volunteers
- 528 people
- Sponsor
- AstraZeneca
Severe Asthma
Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
To evaluate the pharmacokinetics, safety and immunogenicity of BAT2606 in healthy China male subjects.
- Trial name
- NCT05576454
- Testing
- Mepolizumab Injection (BAT2606 Injection), Mepolizumab Injection (EU-licensed Nucala), Mepolizumab Injection (US-licensed Nucala)
- Where
- China
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Asthma
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an…
- Trial name
- REIMAGINE (NCT06041386)
- Testing
- Mepolizumab, Spirometry
- Where
- 65 sites in United States, Belgium and 7 more
- Volunteers
- 336 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.